Newsletter Subject

Breaking News! (NASDAQ: ENSC): Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Platform

From

10xprotrader.com

Email Address

newsletter@10xprotrader.com

Sent On

Mon, May 20, 2024 01:17 PM

Email Preheader Text

Breaking News! Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of In

Breaking News! Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform [Ensysce Biosciences (NASDAQ: ENSC)]( 10XProTrader Member, Hello Kevin Vander here delivering you your new premium alert for Today's 5/20 trading session which is [Ensysce Biosciences Inc. (NASDAQ: ENSC),]( a company making huge strides to combat the opioid crisis. [Breaking News!]( [New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR]( SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product. PF614-MPAR is the Company's Multi-Pill Abuse Protection (MPAR) unique combination opioid product which shuts off opioid release when too many pills are ingested, thereby stopping deliberate or accidental overdose. This ground-breaking technology has the potential to save many lives and was recently granted Breakthrough Therapy designation by the U.S. Food & Drug Administration (FDA). The Phase 1b study, PF614-MPAR-102, will evaluate opioid release following administration of PF614-MPAR at doses of 25 mg, 50 mg and 100 mg delivered twice daily for 5 days to verify both overdose protection and effective delivery of oxycodone. The study will apply the Quotient Sciences Translational Pharmaceutics® platform to manufacture and test the PF614-MPAR drug product to expedite the clinical study process. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, remarked, "My team is delighted to continue our partnership with Quotient Sciences and the use of their unique approach to drug product optimization. Our aim is to provide prescribers and patients with an innovative, safer choice to treat severe pain and reduce substantial concern of overdose. As prescription opioid overdoses remain a critical issue in America, the resultant regulatory restrictions are now causing supply issues for patients in severe pain. The potential benefits of our MPAR platform were highlighted by Dr. Rick Dart at the PAINWeek conference in 2023." About Breakthrough Therapy Breakthrough Therapy is a rarely used designation, having been granted to fewer than 300 drugs since the category was established in 2012. It is designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. About Quotient Sciences Quotient Sciences is a global drug development and manufacturing accelerator that supports companies across the drug development pathway. They provide integrated contract research, development, and manufacturing services for many of the leading global pharma and biotech companies, bringing deep expertise and insight to the development process. The Quotient partnership was instrumental in aiding the development of the first PF614-MPAR 25 mg dosage form using their unique "Translation Pharmaceutics®" process. About Ensysce Biosciences Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit [www.ensysce.com](. Definitions TAAP: trypsin activated abuse protection - designed to protect against prescription drug abuse. MPAR: multi-pill abuse resistance - designed to protect against abuse and accidental overdose. Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible Nasdaq delisting; the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, which are available, free of charge, at the SEC's website at [www.sec.gov](. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. [Read the News here]( Ensynsce Biosciences Has Stacked The Deck Those are value cards that few, if any, Ensynsce Biosciences competitors can play. Frankly, most still need a comparable technology deck to even play from. that's what makes the Ensynsce Biosciences candidate different. Its innovative combination of PF614 with the Multi-Pill Abuse Resistance (MPAR®) technology actually prevents overdose through a mechanism that "turns off" the release of oxycodone if more than the prescribed dose is consumed.]( That could save many of the over 107,000 lives lost in 2023. More than saving a human toll, it could help rehabilitate countless individuals, affected families, and communities. Thus,[Ensysce Biosciences']( isn't only a safer opioid alternative from a scientific perspective, it can be a crucial contributor to the humanitarian effort that can provide hope to millions, save billions of dollars that go toward rehab and incarcerations, and, most importantly, provide essential pain relief to those that need it without the fear of government intrusion that tells doctors what and how much medicine to prescribe. Ironically, microcap company[Ensysce Biosciences]( leading the charge in helping win this critical battle against the opioid crisis. And after a successful capital raise and strategic financial management, they appear to have one of the clearest paths toward regulatory approval for a drug that could eclipse blockbuster-level sales (a billion or more) within weeks of commercialization. Phase 3 Valuation Could Send The ENSC Stock Price Soaring Remember, fellow investors, [Ensysce Biosciences]( isn't starting its clinical trial ambitions; [it's about to enter Phase 3](. It's no secret that the difference in valuations of a Phase 3 company compared to a Phase 2 one can be tens or even hundreds of millions. In other words, don't be surprised to wake up to an ENSC share price of 2X, 3X, or even 10X higher. That potential is indeed in play based on what is likely to be massive interest in this company's late-stage drug pipeline. Don't forget- Ensysce Biosciences is guided to start Phase 3 by mid-year, just weeks away. Still, investing in partnership or buyout speculation is the smallest part of the value proposition exposed. Investors should also be focused on the vast revenue-generating potential in this company's crosshairs. Know this: Going on this project alone certainly wouldn't be the worst option. While it may trigger some dilution, the windfall upon commercialization would most likely dwarf that cost. Thus, with[Ensysce Biosciences]( charging toward a Phase 3 trial with proprietary next-gen drug development platforms, its stock at current prices may present more than a bargain; it may be as ground floor as it gets. And with expected milestones in the queue that could immediately steepen the share price curve, re-claiming its 52-week high of $2.84, 350% higher than its current price, could be a near-term target already in the crosshairs. Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.

Marketing emails from 10xprotrader.com

View More
Sent On

06/06/2024

Sent On

06/06/2024

Sent On

06/06/2024

Sent On

06/06/2024

Sent On

05/06/2024

Sent On

29/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.